Kilian Schober
@kischober.bsky.social
MD Microbiology & Virology. Understanding & Engineering Human T Cell Immunity in Erlangen, Germany (www.schoberlab.de). Cycling. BVB. Cinema. Family.
Pinned
Kilian Schober
@kischober.bsky.social
· Oct 8
TCR activation impairs CAR-T cytotoxicity against separate target cells
Chimeric antigen receptor T cells (CAR-T) are effective therapeutics against cancer and autoimmunity, but whether the endogenous T cell receptor (TCR) is beneficial, detrimental or irrelevant for CAR ...
www.biorxiv.org
When a T cell carries both its natural TCR and an engineered CAR, do these two receptors cooperate - or compete?
Our new preprint on bioRxiv shows that TCR activation can enhance CAR-T activation but impairs CAR-mediated killing when targets are on separate cells.
www.biorxiv.org/content/10.1...
Our new preprint on bioRxiv shows that TCR activation can enhance CAR-T activation but impairs CAR-mediated killing when targets are on separate cells.
www.biorxiv.org/content/10.1...
Reposted by Kilian Schober
(1) Did you ever wonder how effector T cells remodel their transcriptome and proteome when they become activated? and how this remodelling drives T cell diffferentiation? Then you might be interested in our newest preprint:👇
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
www.biorxiv.org
February 4, 2026 at 2:06 PM
(1) Did you ever wonder how effector T cells remodel their transcriptome and proteome when they become activated? and how this remodelling drives T cell diffferentiation? Then you might be interested in our newest preprint:👇
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
Reposted by Kilian Schober
Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial - Nature Medicine
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
www.nature.com
February 3, 2026 at 12:01 AM
Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...
Reposted by Kilian Schober
Online now: Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo
Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo
Mapping TCRs to antigens at scale presents a major challenge. Gaglione et al. develop an approach to rapidly synthesize and screen thousands of TCRs, enabling broad TCR-antigen screening. Examining T cell specificity in vitiligo uncovers autoreactive T cells with transcriptional programs similar to melanoma-reactive T cells, revealing shared features of disease-relevant T cells in autoimmunity and cancer.
dlvr.it
January 28, 2026 at 8:56 PM
Online now: Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo
Reposted by Kilian Schober
Today in @nature.com, we describe how discarded reads in biobank-scale WGS can help resolve the genetic predictors and consequences of Epstein-Barr Virus (EBV) infection.
Wonderful working with @ryandhindsa.bsky.social @sherrynyeo.bsky.social @erinmayc.bsky.social
www.nature.com/articles/s41...
Wonderful working with @ryandhindsa.bsky.social @sherrynyeo.bsky.social @erinmayc.bsky.social
www.nature.com/articles/s41...
Population-scale sequencing resolves determinants of persistent EBV DNA - Nature
Population-scale WGS reveals genetic determinants of persistent EBV DNA, linking immune regulation—especially antigen processing and MHC class II variation—to EBV persistence and heterogeneous di...
www.nature.com
January 28, 2026 at 5:07 PM
Today in @nature.com, we describe how discarded reads in biobank-scale WGS can help resolve the genetic predictors and consequences of Epstein-Barr Virus (EBV) infection.
Wonderful working with @ryandhindsa.bsky.social @sherrynyeo.bsky.social @erinmayc.bsky.social
www.nature.com/articles/s41...
Wonderful working with @ryandhindsa.bsky.social @sherrynyeo.bsky.social @erinmayc.bsky.social
www.nature.com/articles/s41...
Reposted by Kilian Schober
Heute am besten lieber mit Schlittenhunden zur Uni fahren 🐕🦺
January 26, 2026 at 9:53 AM
Heute am besten lieber mit Schlittenhunden zur Uni fahren 🐕🦺
Ich freue mich sehr über diese unglaublich wichtige Förderung unserer Forschung!
Mit welchen Infektionen bist du bereits in Kontakt gekommen? In Zukunft reicht eventuell ein einziger Bluttest, um diese Frage zu beantworten.
Haben die Zellen eine Infektion bekämpft, gehen die meisten von ihnen zugrunde. Einige – die sogenannten Gedächtnis-T-Zellen – überdauern jedoch. (1/2)
Haben die Zellen eine Infektion bekämpft, gehen die meisten von ihnen zugrunde. Einige – die sogenannten Gedächtnis-T-Zellen – überdauern jedoch. (1/2)
January 26, 2026 at 5:59 PM
Ich freue mich sehr über diese unglaublich wichtige Förderung unserer Forschung!
Reposted by Kilian Schober
Sie sorgen dafür, dass das Immunsystem mit diesem spezifischen Erreger künftig leichter fertig wird.
Das diagnostische Potenzial dahinter wird bisher allerdings kaum genutzt. Das soll sich nun ändern: go.fau.de/1dhad (2/2)
Das diagnostische Potenzial dahinter wird bisher allerdings kaum genutzt. Das soll sich nun ändern: go.fau.de/1dhad (2/2)
Bluttest soll Einblick in die Infektionsgeschichte eines Menschen geben
Forschende der FAU und des Uniklinikums Erlangen wollen die Sensoren unter die Lupe nehmen, mit denen das Immunsystem Krankheitserreger erkennt.
go.fau.de
January 26, 2026 at 2:03 PM
Sie sorgen dafür, dass das Immunsystem mit diesem spezifischen Erreger künftig leichter fertig wird.
Das diagnostische Potenzial dahinter wird bisher allerdings kaum genutzt. Das soll sich nun ändern: go.fau.de/1dhad (2/2)
Das diagnostische Potenzial dahinter wird bisher allerdings kaum genutzt. Das soll sich nun ändern: go.fau.de/1dhad (2/2)
Reposted by Kilian Schober
@biorxivpreprint.bsky.social The primary and secondary immune response to Epstein-Barr virus #EBV infection of human tonsil organoids
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
January 17, 2026 at 3:48 AM
@biorxivpreprint.bsky.social The primary and secondary immune response to Epstein-Barr virus #EBV infection of human tonsil organoids
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
Reposted by Kilian Schober
@biorxivpreprint.bsky.social A tonsil organoid model reveals Epstein-Barr virus infected germinal center B cell states during primary infection
www.biorxiv.org/content/10.6... @bgewurz.bsky.social
@harvardmed.bsky.social @ucirvine.bsky.social
www.biorxiv.org/content/10.6... @bgewurz.bsky.social
@harvardmed.bsky.social @ucirvine.bsky.social
January 17, 2026 at 4:23 AM
@biorxivpreprint.bsky.social A tonsil organoid model reveals Epstein-Barr virus infected germinal center B cell states during primary infection
www.biorxiv.org/content/10.6... @bgewurz.bsky.social
@harvardmed.bsky.social @ucirvine.bsky.social
www.biorxiv.org/content/10.6... @bgewurz.bsky.social
@harvardmed.bsky.social @ucirvine.bsky.social
Reposted by Kilian Schober
Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...
January 16, 2026 at 12:00 PM
Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...
Reposted by Kilian Schober
Autoimmunerkrankungen machen den Alltag vieler Menschen schwer. An der FAU wird zur Behandlung von Autoimmunerkrankungen mit CAR-T-Zellen geforscht – und es gibt Grund zur Hoffnung. (1/3)
www.fau.de/2026/01/news...
www.fau.de/2026/01/news...
Hoffnung für Menschen mit schweren Autoimmunerkrankungen durch Erlanger Zelltherapie
FAU-Studie zeigt: Eine einmalige Infusion von CAR-T-Zellen kann Autoimmunerkrankungen stoppen, ohne dass eine weitere Medikamententherapie notwendig ist.
www.fau.de
January 16, 2026 at 7:39 AM
Autoimmunerkrankungen machen den Alltag vieler Menschen schwer. An der FAU wird zur Behandlung von Autoimmunerkrankungen mit CAR-T-Zellen geforscht – und es gibt Grund zur Hoffnung. (1/3)
www.fau.de/2026/01/news...
www.fau.de/2026/01/news...
Reposted by Kilian Schober
January 15, 2026 at 2:09 AM
Reposted by Kilian Schober
Etwa 20 bis 30% aller Menschen, die an Schuppenflechte leiden, entwickeln im Laufe der Zeit zusätzlich eine schmerzhafte Gelenkentzündung. FAU-Forschende haben nun herausgefunden, woran das liegt. Die Erkenntnisse liefern zudem neue Ansätze, wie man eine Entzündung verhindern kann.
go.fau.de/1dghf
go.fau.de/1dghf
Wie Schuppenflechte auf die Gelenke übergreift
Etwa 20 bis 30 Prozent aller Menschen, die an Schuppenflechte leiden, entwickeln zusätzlich eine schmerzhafte Gelenkentzündung. Forschende der FAU habe den Grund dafür gefunden.
go.fau.de
January 13, 2026 at 2:00 PM
Etwa 20 bis 30% aller Menschen, die an Schuppenflechte leiden, entwickeln im Laufe der Zeit zusätzlich eine schmerzhafte Gelenkentzündung. FAU-Forschende haben nun herausgefunden, woran das liegt. Die Erkenntnisse liefern zudem neue Ansätze, wie man eine Entzündung verhindern kann.
go.fau.de/1dghf
go.fau.de/1dghf
Reposted by Kilian Schober
CD19 CAR-T cells for treatment-refractory autoimmune diseases (systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies): the phase 1/2 CASTLE basket trial @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
January 7, 2026 at 10:12 PM
CD19 CAR-T cells for treatment-refractory autoimmune diseases (systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies): the phase 1/2 CASTLE basket trial @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Kilian Schober
New press release from Sanofi - tolebrutinib did NOT meet it's primary endpoint in PP-MS trial
www.sanofi.com/en/media-roo...
www.sanofi.com/en/media-roo...
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to....
www.sanofi.com
December 15, 2025 at 6:28 PM
New press release from Sanofi - tolebrutinib did NOT meet it's primary endpoint in PP-MS trial
www.sanofi.com/en/media-roo...
www.sanofi.com/en/media-roo...
Reposted by Kilian Schober
We have an open call for a group leader at the Rudolf Virchow Center for Integrative and Translational Bioimaging in Würzburg, Germany.
Generous starting package, vibrant and highly interdisciplinary biomedical research environment.
www.nature.com/naturecareer...
Please spread the word.
Generous starting package, vibrant and highly interdisciplinary biomedical research environment.
www.nature.com/naturecareer...
Please spread the word.
Group Leader (f/m/d) at the Rudolf Virchow Center for Integrative and Translational Bioimaging - Würzburg (Stadt), Bayern (DE) job with University of Würzburg - Rudolf Virchow Center for Integrative a...
The Rudolf Virchow Center for Integrative and Translational Bioimaging (RVZ) ist now inviting applications for the position of Group Leader (f/m/d).
www.nature.com
November 21, 2025 at 9:12 PM
We have an open call for a group leader at the Rudolf Virchow Center for Integrative and Translational Bioimaging in Würzburg, Germany.
Generous starting package, vibrant and highly interdisciplinary biomedical research environment.
www.nature.com/naturecareer...
Please spread the word.
Generous starting package, vibrant and highly interdisciplinary biomedical research environment.
www.nature.com/naturecareer...
Please spread the word.
Reposted by Kilian Schober
Less than one week left to apply 🔜
Join us at Charité University and the IMPRS-IDI Graduate Program in Berlin to unravel NK cell clonality and memory! We are looking for motivated PhD candidates who are passionate about immunology. @romagnanilab.bsky.social
@timorckert.bsky.social
Apply now 👉 www.imprs-idi.org/home/
@timorckert.bsky.social
Apply now 👉 www.imprs-idi.org/home/
December 6, 2025 at 2:43 AM
Less than one week left to apply 🔜
Reposted by Kilian Schober
Heute hat die Feierliche Jahressitzung der BAdW im Herkulessaal der Münchner Residenz stattgefunden.
Fotos: Kai Neunert/BAdW
Fotos: Kai Neunert/BAdW
December 6, 2025 at 3:29 PM
Heute hat die Feierliche Jahressitzung der BAdW im Herkulessaal der Münchner Residenz stattgefunden.
Fotos: Kai Neunert/BAdW
Fotos: Kai Neunert/BAdW
Reposted by Kilian Schober
Darwin's regrets:
"If I had to live my life again I would have made a rule to read some poetry and listen to some music at least once every week.. The loss of these tastes is a loss of happiness, and may possibly be injurious to the intellect and more probably to the moral character"
"If I had to live my life again I would have made a rule to read some poetry and listen to some music at least once every week.. The loss of these tastes is a loss of happiness, and may possibly be injurious to the intellect and more probably to the moral character"
December 5, 2025 at 3:01 AM
Darwin's regrets:
"If I had to live my life again I would have made a rule to read some poetry and listen to some music at least once every week.. The loss of these tastes is a loss of happiness, and may possibly be injurious to the intellect and more probably to the moral character"
"If I had to live my life again I would have made a rule to read some poetry and listen to some music at least once every week.. The loss of these tastes is a loss of happiness, and may possibly be injurious to the intellect and more probably to the moral character"
Reposted by Kilian Schober
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells @nature.com #Germain @niaidnews.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 26, 2025 at 5:36 PM
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells @nature.com #Germain @niaidnews.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Kilian Schober
We are #absolutely #thrilled to #present @cp-immunity.bsky.social - Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils: Immunity www.cell.com/immunity/ful...
Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils
Human T cell responses are often studied using blood, yet most T cells reside in tissues.
By comparing T cell receptor repertoires from millions of T cells from autologous
tonsils and blood, Sureshcha...
www.cell.com
November 26, 2025 at 3:47 PM
We are #absolutely #thrilled to #present @cp-immunity.bsky.social - Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils: Immunity www.cell.com/immunity/ful...
Reposted by Kilian Schober
‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission
Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results @nature.com
www.nature.com/articles/d41...
Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results @nature.com
www.nature.com/articles/d41...
November 26, 2025 at 3:12 PM
‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission
Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results @nature.com
www.nature.com/articles/d41...
Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results @nature.com
www.nature.com/articles/d41...
Reposted by Kilian Schober
Agentic AI systems are becoming available for use in science – but can we trust them?
November 26, 2025 at 12:55 PM
Agentic AI systems are becoming available for use in science – but can we trust them?
Reposted by Kilian Schober
Excited to see our TIRTL-seq method published in Nature Methods www.nature.com/articles/s41...! Some updates after the revision: (1/4)
TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing - Nature Methods
TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.
www.nature.com
November 25, 2025 at 10:38 PM
Excited to see our TIRTL-seq method published in Nature Methods www.nature.com/articles/s41...! Some updates after the revision: (1/4)